에 대한 최신 뉴스 ImmunityBio (NASDAQ:IBRX) 주식

IMMUNITYBIO INC

ImmunityBio

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

San,Jose,,California,Us,-,February,14,,2025:,Archer,Brand

Equities

Mid Cap

News

Movers

ACHR

DBRG

DGNX

IBRX

LUNR

OKLO

지난주 최고의 성과를 거둔 중형주는 다음과 같다. 풋락커, 아처 에비에이션, 디지털브릿지, 뉴스케일 파워, 디지넥스, 이뮤니티바이오, 오클로, 인튜이티브 머신스

풋락커·아처에비에이션 등 지난주 급등한 중형주 8종목 (5월 12~16일)

Quantum Computing

Trading Ideas

ALHC

BPMC

COMP

HEES

IONQ

MSFT

NVDA

OPCH

SEMR

1월 13일부터 17일까지 지난주에 최고의 실적을 거둔 중형주 8종목은 다음과 같다 .H&amp;E 이큅먼트 SEM러시 컴퍼스 블루프린트 얼라인먼트 옵션 케어 이뮤니티바이오 아이온큐

아이온큐, H&amp;E 이큅먼트, 이뮤니티바이오 등 지난주 급등한 중형주 (1월 13일~17일)

$BTC

IRTC

WULF

이들 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이뮤니티바이오(NASDAQ:IBRX)의 주식은 회사가 재발성 B-세포 비호지킨 림프종에 대한 CAR-NK 세포 치료제의 1상 임상 연구에서 첫 환자에게 투여했다고 발표한 후 49.86% 상승했다.

트럼프 미디어와 스트라이드는 지난주 최고 성과를 보여준 10개 중형주 중 일부 (10월 21일-10월 25일)

ImmunityBio Inc

Second Patient in first cohort enrolled and treated at the Royal North Shore Hospital/University of Sydney
Aethlon Advances Hemopurifier&#xAE; Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies
SAN DIEGO, June 18, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4451389-1&amp;h=3638213646&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fwww.aethlonmedical.com%2F___.YXAzOmFldGhsb246YTpvOjhhMGQxZTQ5ODhlNGJjNDNiOTFiOWI3OGQyNTg0NTkyOjY6YjRmZDo1ZDY5N2I5YTA1MGRiODQyMmUyM2NlODE0ODI1OGExZWQzZGVlYzFiODQ3YjNjMmU4YmZjMzY0ZjE1OGJiZmU0OnA6Rg&amp;a=Aethlon+Medical%2C+Inc.">Aethlon Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: the treatment of the second patient with the&nbsp;Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda&#xAE; (pembrolizumab) or Opdivo&#xAE; (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was treated with the Hemopurifier June 11, 2025 by Genesis Care and Royal North Shore Hospital/University of Sydney. Professor Stephen Clarke, Medical Oncologist, is the Principal Investigator for the study and the Hemopurifier session was supervised by Dr. Emma O'Lone.
Ongoing progress has been made in our Australian Oncology trial of the Hemopurifier in participants with solid tumors not responding to anti-PD-1 agents. We have now completed Hemopurifier treatments in 2 participants in the first cohort. Our first participant completed the Hemopurifier treatment at Royal Adelaide Hospital on January 29, 2025. Participant # 2 was treated with the Hemopurifier at Royal North Shore/University of Sydney on June 2, 2025. Both participants completed the 4-hour Hemopurifier treatment without device deficiencies or immediate complications. As of June 10, 2025, both patients have completed the pre-specified 7-day safety follow-up period that will be presented to an independent Data Safety Monitoring Board (DSMB) following the treatment of a third patient in the cohort.
The DSMB will review safety data on this first cohort and provide a recommendation to Aethlon Medical Senior Leadership about advancing to the second treatment cohort where 3 participants will receive 2 Hemopurifier treatments during a one-week period. We would expect data on extracellular removal by the Hemopurifier and effects on anti-tumor T cell activity on participants in the first cohort in approximately three months following enrollment of the third patient.

Biotech

General

AEMD

Aethlon Medical Treats Second Patient In Australian Hemopurifier Trial For Solid Tumors Unresponsive To Anti-PD-1 Therapy At Royal North Shore Hospital/University Of Sydney

<h3>Gainers</h3>
<ul>
<li>Lottery.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRY#NASDAQ">LTRY</a>) stock increased by 16.4% to $1.28 during Wednesday's pre-market session. The market value of their outstanding shares is at $34.1 million. </li>
<li>Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) stock rose 15.56% to $1.93. The market value of their outstanding shares is at $37.9 million. </li>
<li>Hour Loop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOUR#NASDAQ">HOUR</a>) stock moved upwards by 14.98% to $1.4. The market value of their outstanding shares is at $49.0 million. </li>
<li>Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) shares increased by 10.42% to $3.6. The market value of their outstanding shares is at $129.5 million. </li>
<li>U Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) shares rose 7.33% to $3.95. The company's market cap stands at $17.4 million. </li>
<li>QuantaSing Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) stock increased by 6.11% to $13.88. The company's market cap stands at $709.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) shares declined by 7.7% to $0.95 during Wednesday's pre-market session. The market value of their outstanding shares is at $9.4 million. </li>
<li>ZHONGCHAO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) shares decreased by 6.95% to $1.2. The market value of their outstanding shares is at $30.3 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) stock decreased by 6.83% to $7.2. The market value of their outstanding shares is at $124.1 million. </li>
<li>Springview Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) stock decreased by 5.82% to $0.52. The market value of their outstanding shares is at $5.9 million. </li>
<li>Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) stock decreased by 5.41% to $1.4. The company's market cap stands at $17.6 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Mixed Martial Arts Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MMA#AMEX">MMA</a>) stock fell 4.77% to $1.0. The market value of their outstanding shares is at $12.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HOUR

LTRY

SPHL

UCAR

VNCE

ZCMD

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock increased by 180.5% to $7.91 during Wednesday's pre-market session. The company's market cap stands at $5.3 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock moved upwards by 51.95% to $1.21. The market value of their outstanding shares is at $3.4 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 36.12% to $6.82. The company's market cap stands at $6.9 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares increased by 23.48% to $0.38. The market value of their outstanding shares is at $1.2 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock increased by 21.94% to $3.39. The company's market cap stands at $88.4 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares rose 17.82% to $1.06. The market value of their outstanding shares is at $16.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock declined by 26.8% to $14.52 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.9 million. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) stock fell 22.02% to $0.64. The market value of their outstanding shares is at $15.0 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock declined by 19.65% to $0.23. The market value of their outstanding shares is at $20.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock decreased by 15.07% to $5.92. The market value of their outstanding shares is at $17.0 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 13.11% to $1.26. The company's market cap stands at $90.1 million. </li>
<li>Crescent Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) shares declined by 10.78% to $11.84. The company's market cap stands at $230.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACXP

APVO

BDRX

CBIO

CERO

CTOR

EYEN

GOVX

HSDT

SNTI

STSS

XAIR

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) stock rose 10.5% to $0.2 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.7 million. </li>
<li>Euroseas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESEA#NASDAQ">ESEA</a>) stock moved upwards by 10.01% to $49.54. The market value of their outstanding shares is at $347.1 million. As per the press release, Q1 earnings came out today. </li>
<li>KULR Technology Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) stock moved upwards by 9.61% to $0.83. The market value of their outstanding shares is at $253.6 million. </li>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) stock rose 9.32% to $1.29. The company's market cap stands at $20.9 million. </li>
<li>Eve Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) stock moved upwards by 8.88% to $5.88. The market value of their outstanding shares is at $1.7 billion. </li>
<li>Korn Ferry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFY#NYSE">KFY</a>) stock rose 8.59% to $72.5. The company's market cap stands at $3.7 billion. As per the press release, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CDT Envirn Tech Inv Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) shares decreased by 11.2% to $0.93 during Wednesday's pre-market session. The company's market cap stands at $11.4 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) stock fell 7.36% to $0.08. The market value of their outstanding shares is at $11.8 million. </li>
<li>3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) stock fell 6.96% to $1.74. The company's market cap stands at $237.3 million. </li>
<li>Performance Shipping (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSHG#NASDAQ">PSHG</a>) stock decreased by 6.87% to $1.9. The market value of their outstanding shares is at $23.6 million. </li>
<li>Founder Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGL#NASDAQ">FGL</a>) stock decreased by 6.84% to $0.77. The market value of their outstanding shares is at $15.0 million. </li>
<li>Globus Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBS#NASDAQ">GLBS</a>) shares fell 6.72% to $1.25. The market value of their outstanding shares is at $25.7 million. The company's, Q1 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CDTG

DXST

ESEA

EVEX

GLBS

KULR

PSHG

RYDE

12 Industrials Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Intchains Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) stock moved upwards by 17.4% to $1.96 during Wednesday's pre-market session. The market value of their outstanding shares is at $118.3 million. </li>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) stock rose 9.41% to $0.18. The company's market cap stands at $10.5 million. </li>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) stock moved upwards by 8.63% to $0.41. The market value of their outstanding shares is at $26.0 million. </li>
<li>Cloudastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>) stock increased by 8.1% to $2.0. The market value of their outstanding shares is at $33.8 million. </li>
<li>MultiSensor AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSAI#NASDAQ">MSAI</a>) stock increased by 7.89% to $0.73. The market value of their outstanding shares is at $24.5 million. </li>
<li>GCT Semiconductor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCTS#NYSE">GCTS</a>) stock moved upwards by 7.4% to $1.45. The market value of their outstanding shares is at $80.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) shares fell 9.4% to $0.25 during Wednesday's pre-market session. The company's market cap stands at $16.3 million. </li>
<li>FiEE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) shares declined by 7.14% to $2.58. The market value of their outstanding shares is at $18.9 million. </li>
<li>Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) stock decreased by 6.7% to $11.85. The market value of their outstanding shares is at $2.3 billion. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock declined by 6.41% to $9.21. The market value of their outstanding shares is at $153.6 million. </li>
<li>T Stamp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) shares fell 5.98% to $1.89. The market value of their outstanding shares is at $4.6 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) shares fell 4.93% to $0.88. The company's market cap stands at $22.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBK

BTDR

BTOG

CSAI

GCTS

IDAI

MINM

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

TDTH

12 Information Technology Stocks Moving In Wednesday's Pre-Market Session

PodcastOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODC#NASDAQ">PODC</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 50 percent. This is a 20 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $14.10 million which beat the analyst consensus estimate of $13.11 million by 7.51 percent. This is a 20.42 percent increase over sales of $11.71 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

PODC

PodcastOne Q4 EPS $(0.06) Misses $(0.04) Estimate, Sales $14.10M Beat $13.11M Estimate

IMNN

IMUNON Highlights Presentation Of Translational Data From Phase 2 OVATION 2 Study Of IMNN-001

Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) (the "Company") today announced that it has entered into a definitive agreement with an institutional investor (the "SPA") for the purchase and sale of an aggregate of 223,762 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $10.60 per share (or pre-funded warrant in lieu thereof) in a registered direct offering (the "Offering").&nbsp;
The aggregate gross proceeds to the Company of this offering are expected to be approximately $2.37 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds of approximately $2.1 million from the offering for general corporate purposes. The transaction is expected to close on or about June 20, 2025, subject to the satisfaction of customary closing conditions.

Offerings

HUSA

Houston American Energy Corp Enters Definitive Agreement For $2.37M Registered Direct Offering Of  223,762 Shares Of Common Stock And Pre-Funded Warrants At $10.60 Per Share To Institutional Investor

Regulatory Approval by the UK Financial Conduct Authority was Key Requirement for Transaction Timing
Minimal Conditions Remain for Deal Completion; Closing Expected in July, 2025
&nbsp;Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) ("TRNR" or the "Company") today announced that it has received formal approval from the UK Financial Conduct Authority ("FCA") for its previously-announced acquisition of Wattbike, the UK-based, omni-channel, connected, indoor-performance bike business, and that it expects to complete the acquisition in July, 2025.
The FCA's approval satisfies a key condition for the closing of the acquisition, which is expected to significantly expand Interactive Strength Inc.'s presence in the global fitness market, particularly in the UK, and enhance its product offerings with a leading indoor-performance bike offering. This strategic acquisition is anticipated to be immediately accretive to TRNR's results and accelerate growth, especially in key markets like the US and Germany, leveraging TRNR's global distribution network.
Wattbike delivered over $15 million in 2024 revenue and has built on its prestigious elite-sport base - including Olympic teams, Premier League clubs, major US sports teams and elite fitness facilities - to debut a much broader product portfolio that will allow its footprint to scale internationally as well as in the UK, its home market.
"We have been waiting to secure FCA approval in order to finalize the Wattbike deal and now we will push to completion quickly," said Trent Ward, Founder &amp; CEO of Interactive Strength. "This regulatory hurdle was the main closing requirement the timing of which we did not control. The remaining steps are largely administrative. We're already well underway integrating and collaborating with Wattbike, and we look forward to accelerating from here. Wattbike's elite heritage, combined with TRNR's Nasdaq listing, US distribution reach, and marketing muscle, positions us to drive meaningful growth across the UK, US, and Germany."
"We remain thrilled to become part of the TRNR family," added Stephen Loftus, CEO of Wattbike. "With FCA approval secured, we're on the road to fully leverage TRNR's global platform to accelerate our consumer and commercial expansion and bring premium, data-driven indoor cycling to new audiences."
Wattbike is renowned for its high-performance connected indoor bikes, with deep penetration into leading UK gyms and an expanding direct-to-consumer customer base. The acquisition consideration is structured as an all-stock transaction for 100% of Wattbike, and there is an earn-out component to align the business' financial performance with TRNR valuation. Further details regarding the financial impact of the acquisition will be provided in our upcoming filings with the U.S. Securities and Exchange Commission.

TRNR

Interactive Strength Announces It Has Received Formal Approval From The UK Financial Conduct Authority For Previously-Announced Acquisition Of Wattbike And Expects To Complete The Acquisition In July, 2025

Ancora Holdings Group, LLC (together with its affiliates, "Ancora" or "we") today issued the below statement following its decision to redeem its investment in the long-term special purpose vehicle managed by Hestia Capital Management LLC and, in turn, start directly holding its shares of Pitney Bowes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) ("Pitney Bowes" or the "Company") due to the size of the position.
Fredrick D. DiSanto, Chairman and Chief Executive Officer of Ancora Holdings Group LLC, and James Chadwick, President of Ancora Alternatives LLC, commented:
"We originally invested in Kurt Wolf's special purpose vehicle because we believed Kurt could be a catalyst of significant value creation at Pitney Bowes. More than two years later, Kurt has clearly been the driving force behind the Company's cost reductions, cash repatriation initiatives, debt reduction and the necessary divestiture of the Global Ecommerce unit. The excellent results speak for themselves. We look forward to remaining long term investors in Pitney Bowes and believe shareholders are well served by Kurt Wolf as the Company's Chief Executive Officer."

Ancora Redeems Investment In Hestia Special Purpose Vehicle, Now Directly Holding Pitney Bowes Shares

Guidance

STLD

Steel Dynamics Sees Q2 EPS $2.00-$2.04

85% remission rate observed in evaluable frontline AML patients
Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient
No dose-limiting toxicities observed among evaluable patients; safety profile remains strong
Evidence mounts for mipletamig as a potentially transformational addition to standard of care in frontline AML as targeted CD123 x CD3 approach showing power and precision, limited added toxicity
Mipletamig Trial Momentum Builds as Cohort 3 Nears Full Enrollment at highest dose level evaluated to date in combination therapy
SEATTLE, WA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 18, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on its proprietary ADAPTIR&#xAE; and ADAPTIR-FLEX&#xAE; platform technologies, today announced new clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig, its first-in-class CD123 x CD3 bispecific antibody, in combination with standard-of-care venetoclax and azacitidine (ven/aza) for newly diagnosed patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy.
Across two trials, the mipletamig triplet therapy delivered remissions in 85% of evaluable frontline AML patients-which significantly exceeds results from competitor studies, including those achieved in the Viale A trial that evaluatedvenetoclax and azacitidine (ven/aza) as doublet therapy. These updated results from the RAINIER dose expansion trial continue to demonstrate a compelling efficacy advantage alongside a strong safety profile. No cytokine release syndrome (CRS) was observed in either cohorts 1 or 2. Cohort 3 Nears Full Enrollment at highest dose level evaluated to date in combination therapy.

Aptevo Therapeutics Reports 85% Remission Rate In Frontline AML With Mipletamig Combination, No Dose-Limiting Toxicities, Enables Transplant In Previously Ineligible Patient; Advances High-Dose Cohort Enrollment In RAINIER Trial

TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>), a leading provider of golf simulator software and hardware, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split of its Class A common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on June 23, 2025, and the Company's Class A common stock will open for trading on The Nasdaq Capital Market on June 23, 2025 on a post-split basis, under the existing ticker symbol "TRUG" but with a new CUSIP number 243733409.
As a result of the reverse stock split, every fifty shares of the Company's Class A common stock issued and outstanding prior to the opening of trading on June 23, 2025 will be consolidated into one issued and outstanding share. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's outstanding equity awards, as applicable, as well as to the number of shares issuable under the Company's equity incentive plans. The Class A common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the number of authorized shares of Class A common stock or the par value of the Class A common stock. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would become entitled to a fractional share because the number of shares of Class A common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, the stockholder will be entitled to receive a cash payment in lieu of a fractional share.

Stock Split

TRUG

TruGolf Announces A 1-For-50 Reverse Stock Split, Effective June 23, 2025

Euroseas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESEA#NASDAQ">ESEA</a>) reported quarterly earnings of $3.76 per share which beat the analyst consensus estimate of $3.28 by 14.63 percent. This is a 41.35 percent increase over earnings of $2.66 per share from the same period last year. The company reported quarterly sales of $56.35 million which beat the analyst consensus estimate of $52.91 million by 6.49 percent. This is a 20.61 percent increase over sales of $46.72 million the same period last year.

Euroseas Q1 Adj. EPS $3.76 Beats $3.28 Estimate, Sales $56.35M Beat $52.91M Estimate

Intelligent Bio Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) on Wednesday announced that Managed Waste Service plans to implement INBS' Intelligent Fingerprinting Drug Screening System across its New South Wales operations, including its land clearing and <a href="https://www.benzinga.com/exclusives" target="_blank" rel="noreferrer noopener">green waste processing sites</a>.
Managed Waste Service is an Australia-based waste management provider.
The decision marks Managed Waste Service's first move into in-house drug testing across multiple locations. More than 20 sites are engaged in remote testing operations.
Managed Waste Service plans to conduct pre-employment, random, and for-cause testing on-site, giving operational teams complete control over safety processes without the disruption associated with traditional outsourced models.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45372843/exclusive-intelligent-bio-solutions-q3-gross-profit-jumps-by-91" rel="noreferrer noopener">EXCLUSIVE: Intelligent Bio Solutions Q3 Gross Profit Jumps By 91%</a>
<h2 class="wp-block-heading">Why It Matters</h2>
The Intelligent Fingerprinting Drug Screening System offers a quick, noninvasive method of screening for recent drug use through fingerprint sweat analysis, delivering results in under ten minutes.
Intelligent Bio Solutions' technology enables Managed Waste Service to implement a scalable, portable solution that aligns with the nature of their fieldwork, whether testing at a remote clearing site or managing compliance across several waste facilities simultaneously.
This implementation reflects Intelligent Bio Solutions' continued expansion into safety-critical industries, with environmental services now joining a growing portfolio of sectors adopting sweat-based drug testing.
Intelligent Bio Solutions provides drug testing.
Over 450 organizations in 24 countries use its technology to streamline and simplify workplace testing.
In June, SMARTOX, a U.S.-based provider of drug and alcohol testing products and services, said it deployed over 50 Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including over 1,500 tests <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45880764/exclusive-intelligent-bio-solutions-expands-us-forensic-market-presence-seeks-fda-clearance-for-fingerprint-drug-testing" rel="noreferrer noopener">in 2024 alone</a>.
As adoption grows in the U.S. Forensic Use Only market, Intelligent Bio continues to actively pursue FDA clearance for its opiate test system for codeine.
This effort aims to enable expansion into broader U.S. markets this year, including workplace drug testing, using its innovative fingerprint sweat-based testing technology.
Price Action: INBS stock is up 1.55% at $1.96 during the premarket session at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/45982666/fda-introduces-tumor-board-style-reviews-for-faster-drug-decisions" target="_blank" rel="noreferrer noopener">FDA Introduces Tumor Board-Style Reviews For Faster Drug Decisions</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

Intelligent Bio Solutions Inc. - Common Stock

INBS

EXCLUSIVE: Intelligent Bio's Fingerprint Drug Testing Gains Momentum With New Australian Rollout

Alkami Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKT#NASDAQ">ALKT</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $39.4, a high estimate of $46.00, and a low estimate of $30.00. This current average represents a 13.22% decrease from the previous average price target of $45.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1750248102_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Alkami Technology. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ella Smith</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jacob Stephan</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$46.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alkami Technology. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Alkami Technology compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Alkami Technology's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Alkami Technology's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALKT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alkami Technology analyst ratings.</a>
<h2>About Alkami Technology</h2>
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company's solution, the Alkami Digital Banking Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency, all with the support of a proprietary, true cloud-based, multi-tenant architecture.
<h3>Unraveling the Financial Story of Alkami Technology</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Alkami Technology's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 28.52%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Alkami Technology's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Alkami Technology's ROE stands out, surpassing industry averages. With an impressive ROE of -2.26%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Alkami Technology's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.23%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.24.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ALKT

Assessing Alkami Technology: Insights From 5 Financial Analysts

LiveOne Q4 EPS $(0.08) Misses $(0.04) Estimate, Sales $19.29M Miss $22.26M Estimate

In the last three months, 20 analysts have published ratings on Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Ralph Lauren, revealing an average target of $297.8, a high estimate of $384.00, and a low estimate of $205.00. Marking an increase of 4.13%, the current average surpasses the previous average price target of $286.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1750248044_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Ralph Lauren by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$384.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Heather Balsky</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$328.00</td>
<td>$318.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$324.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$295.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Underperform</td>
<td>$205.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$321.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ashley Helgans</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$328.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$335.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$262.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$282.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ralph Lauren. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ralph Lauren compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Ralph Lauren's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Ralph Lauren's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ralph Lauren analyst ratings.</a>
<h2>Get to Know Ralph Lauren Better</h2>
Founded by designer Ralph Lauren in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle merchandise in North America, Europe, and Asia. Best known for its iconic polo shirts, its products also include other types of apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
<h3>Understanding the Numbers: Ralph Lauren's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Ralph Lauren's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.25% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.6%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ralph Lauren's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.03% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.83%, the company showcases effective utilization of assets.
Debt Management: Ralph Lauren's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.03.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 20 Analyst Ratings Have To Say About Ralph Lauren

EXCLUSIVE: Intelligent Bio Solutions Tells Benzinga Co. Launches In-House Fingerprint Drug Testing Across 20+ Sites Major Australian Waste Operator, Says Accelerating APAC Expansion

HC Wainwright &amp; Co. analyst Joseph Pantginis assumes Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announces Price Target of $41.

Price Target

Initiation

CDTX

HC Wainwright & Co. Assumes Cidara Therapeutics at Buy, Announces Price Target of $41

Press Releases

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Opinion

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry

ANIX

IOVA

ONCY

REGN

TSX:ONC

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

CG Oncology

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

Immunovant

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Viking Therapeutics

HC Wainwright & Co.

D. Boral Capital

Piper Sandler

BTIG

지난주 최고의 성과를 거둔 중형주는 다음과 같다.
<ol class="wp-block-list">
<li>풋락커(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) 주가는 약 98.58% 급등했다, 딕스 스포팅 굿즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>)가 약 24억 달러의 자본가치로 회사를 인수하기로 합의한 이후였다. 또한 회사는 <a href="https://www.benzinga.com//node/45435748" target="_blank" rel="noreferrer noopener">1분기 예비 실적</a>을 발표했으며 여러 애널리스트가 <a href="https://www.benzinga.com/quote/fl/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 상향 조정</a>했다.</li>
<li>아처 에비에이션 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) 주가는 50.96% 상승했다, 회사가 예상보다 나은 주당순이익(EPS) 결과를 보고하고 <a href="https://www.benzinga.com//node/45443360" target="_blank" rel="noreferrer noopener">LA28 올림픽 및 패럴림픽 게임</a>의 공식 에어택시(air taxi) 제공업체가 되는 독점 파트너십을 발표했기 때문이다.</li>
<li>디지털브리지 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBRG#NYSE">DBRG</a>) 주가는 38.63% 증가했다. 트레이더들은 &#8217;26North&#8217;가 회사를 인수하기 위한 협상을 진행 중이라는 확인되지 않은 인수 소문을 돌리고 있다.</li>
<li>뉴스케일 파워(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) 주가는 38.51% 상승했으며, 이는 <a href="https://www.benzinga.com//node/45383335" target="_blank" rel="noreferrer noopener">1분기 실적 발표</a> 이후 올랐다.</li>
<li>디지넥스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) 주가는 38.37% 급등했다.</li>
<li>이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) 주가는 회사가 <a href="https://www.benzinga.com//node/45343007" target="_blank" rel="noreferrer noopener">예상보다 나은 실적</a>을보고한 이후 37.20% 상승했다.</li>
<li>오클로(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) 주가는 전년 대비 <a href="https://www.benzinga.com//node/45472603" target="_blank" rel="noreferrer noopener">1분기 실적 개선</a>을 보고한 이후 34.28% 상승했다.</li>
<li>인튜이티브 머신스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) 주가는 회사가 <a href="https://www.benzinga.com//node/45400804" target="_blank" rel="noreferrer noopener">예상치를 웃도는 중간값으로 FY25 매출 가이던스</a>를 발표한 이후 33.77% 상승했다.</li>
</ol>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

1월 13일부터 17일까지 지난주에 최고의 실적을 거둔 중형주 8종목은 다음과 같다.
<ol>
<li>H&amp;E 이큅먼트 서비시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEES#NASDAQ">HEES</a>): 유나이티드 렌탈스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>)가 약 <a href="https://www.benzinga.com//node/42974291" target="_blank" rel="noreferrer noopener">48억 달러에 H&amp;E 이큅먼트를 인수하겠다고 발표</a>한 후 100.59% 급등했다. UBS는 H&amp;E 이큅먼트 투자의견을 매수에서 중립으로 하향 조정하고, 목표주가를 <a href="https://www.benzinga.com/quote/HEES/analyst-ratings" target="_blank" rel="noreferrer noopener">60달러에서 92달러로 상향 조정</a>했다.</li>
<li>SEM러시 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>): 미국 소비자물가지수(CPI) 데이터가 예상과 일치하고 근원 CPI가 예상보다 적게 상승하면서 전체 시장이 강세를 보인 후 36.17% 상승했다. 또한 모건스탠리는 회사에 대한 투자의견을 중립에서 비중확대로 상향 조정하고, <a href="https://www.benzinga.com/quote/semr/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 17달러에서 20달러로 상향 조정</a>했다.</li>
<li>컴퍼스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>): 회사가 <a href="https://www.benzinga.com//node/42997946" target="_blank" rel="noreferrer noopener">4분기 및 2024회계연도 가이던스를 상향 조정</a>한 후 26.36% 상승했다.</li>
<li>블루프린트 메디슨스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>): 회사가 <a href="https://www.benzinga.com//node/42935745" target="_blank" rel="noreferrer noopener">2024 회계연도 AYVAKIT 매출 실적이 전년 대비 증가</a>했다고 발표한 후 25.87% 상승했다.</li>
<li>얼라인먼트 헬스케어(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>): 지난주 22.73% 상승했다.</li>
<li>옵션 케어 헬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>): 회사가 5억 달러 규모의 새로운 자사주매입 프로그램을 승인하고, 2024회계연도 조정 EPS 가이던스를 예상치를 상회한다고 발표한 후 21.55% 상승했다. 바링턴 리서치(Barrington Research)는 회사에 대한 시장수익률 상회 의견을 유지하고, <a href="https://www.benzinga.com/quote/OPCH/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 32달러에서 33달러로 상향 조정</a>했다.</li>
<li>이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>):ㅜ 회사가 진행 중인 미 식품의약국(FDA)과 논의에 대한 업데이트를 제공한 후 21.49% 상승했다. 논의된 세 가지 분야는 비근육 침윤성 방광암(NMIBC) 및 <a href="https://www.benzinga.com//node/43038889" target="_blank" rel="noreferrer noopener">비소세포폐암(NSCLC)</a>이다.</li>
<li>아이온큐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>): 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)가 비즈니스 고객에게 &#8220;퀀텀 레디&#8221;를 하라고 발언한 후 20.29% 급등했다. 또한 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)가 <a href="https://www.benzinga.com/25/01/43011494/whats-going-on-with-ionq-stock-today" target="_blank" rel="noreferrer noopener">첫 번째 &#8216;퀀텀 데이&#8217; 이벤트</a>를 발표했다.</li>
</ol>
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C%EC%8A%A4%ED%8A%B8%EB%A0%88%ED%8B%B0%EC%A7%80-%EC%86%8C%ED%8C%8C%EC%9D%B4-%ED%85%8C%ED%81%AC%EB%86%80%EB%A1%9C%EC%A7%80%EC%8A%A4-%EC%B9%B4%EB%B0%94%EB%82%98/">마이크로스트레티지, 소파이 테크놀로지스, 카바나 등 지난주 급등한 대형주 (1월 13일~1월 17일)</a>
이미지 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

아이온큐, H&E 이큅먼트, 이뮤니티바이오 등 지난주 급등한 중형주 (1월 13일~17일)

이들 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)의 주식은 회사가 재발성 <a href="https://www.benzinga.com//node/41516867" target="_blank" rel="noreferrer noopener">B-세포 비호지킨 림프종</a>에 대한 CAR-NK 세포 치료제의 1상 임상 연구에서 첫 환자에게 투여했다고 발표한 후 49.86% 상승했다.
2. 스트라이드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>)의 주식은 회사가 1분기 실적이 예상보다 좋게 나타났고, 2025 회계연도 및 2분기 <a href="https://www.benzinga.com//node/41487340" target="_blank" rel="noreferrer noopener">매출 가이던스도 예상치를 상회</a>했다고 발표한 후 41.43% 급등했다. 애널리스트들이 <a href="https://www.benzinga.com/quote/lrn/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표</a>를 올렸다.
3. 퓨어사이클 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>)의 <a href="https://www.benzinga.com//node/41409452" target="_blank" rel="noreferrer noopener">주식은 32.21% 상승</a>했다.
4. 트럼프 미디어 앤 테크놀로지 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)의 주식은 지난주에 31.68% 상승했다. 이 주식은 다가오는 미국 선거를 앞두고 변동성을 보였다.
5. 지커 인텔리전트 테크놀러지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>)의 주식은 29.31% 상승했다. 여러 미국 상장 중국 주식들이 인민은행이 <a href="https://www.benzinga.com//node/41547149" target="_blank" rel="noreferrer noopener">7,000억 위안</a> (약 983억 6천만 달러)를 은행 시스템에 주입하고 금리를 2.0%로 유지했다고 발표한 후 상승했다.
6. 아이온큐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>)의 주식은 27.52% 상승했다.
7. 허크 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>)의 주식은 회사가 3분기 매출 실적이 예상보다 좋았고 2024 회계연도 장비 <a href="https://www.benzinga.com//node/41455862" target="_blank" rel="noreferrer noopener">임대 매출 성장 전망을 상향 조정</a>했다고 발표한 후 21.76% 상승했다.
8. 테라울프(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>)의 주식은 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 가격 상승으로 18.59% 상승했다. 이 회사는 또한 4억 2,500만 달러를 전환사채로 조달할 것을 제안했다.
9. 아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41462205" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">지오(Zio) AT 기기</a>의 이전 설계 변경과 관련된 510(k) 제출에 대해 FDA 승인을 받았다고 발표한 후 주가가 20.76% 상승했다.
10. 셀레스티카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>)의 주식은 회사가 3분기 실적이 예상보다 좋았고 4분기 매출 가이던스를 예상치를 상회한다고 발표한 후 19.99% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/41523564" target="_blank" rel="noreferrer noopener">주가 목표</a>를 올렸다.
또한 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%85%8C%EC%8A%AC%EB%9D%BC%EC%99%80-%EB%A6%AC-%EC%98%A4%ED%86%A0%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10%EA%B0%9C-%EB%8C%80/" target="_blank" rel="noopener">테슬라와 리 오토는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 21일-10월 25일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%A0%9C%EB%89%B4%EC%9D%B8-%ED%8C%8C%EC%B8%A0-%EB%B0%8F-%ED%83%91%EB%B9%8C%EB%93%9C%EA%B0%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%9D%B8-10/" target="_blank" rel="noopener">제뉴인 파츠 및 탑빌드가 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 21일-10월 25일)</a></li>
</ul>
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 중형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>빌리빌리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>)의 주가는 지난주 &#8216;산구오: 무딩티엔샤(San Guo: Mou Ding Tian Xia)&#8217; 발표 이후 23.32% 상승했다. 또한 JP모건 애널리스트 다니엘 첸(Daniel Chen)은 중국의 빌리빌리를 중립에서 비중확대로 상향 조정하고 <a href="https://www.benzinga.com//node/39418621" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">21</a>달러 가격 목표를 발표했다.</li>
<li>이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)의 주가는 안크티바(ANKTIVA)가 여러 주에 걸쳐 <a href="https://www.benzinga.com//node/39417764" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">첫 번째 상용 투여량</a>을 투여한 보험 적용 범위를 발표한 이후 지속적인 강세로 22.36% 상승했다.</li>
<li>사솔(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>)은 회사가 법원에서 회사와 토탈에너지스 SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) 마켓팅에 유리한 판결을 내렸다고 발표한 후 주가는 20.89% 상승했다. 또한 손해배상금으로 38.9억 랜드, <a href="https://www.benzinga.com//node/39412202" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">이자로 약 2,300만 랜드</a>를 받았다.</li>
<li>지난주 올리즈 바겐 아울렛 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>)의 주식은 JP모건이 중립에서 <a href="https://www.benzinga.com/quote/OLLI/analyst-ratings">비중확대</a>로 평가를 올린 이후 15.25% 상승했다.</li>
<li>인트라-셀룰러 테라피스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)는 회사가 루마테페론을 주요 우울 장애 환자를 위한 보조 요법으로 평가하고 <a href="https://www.benzinga.com//node/39382029" target="_blank" rel="noreferrer noopener">1차 및 주요 2차 평가변수를 충족</a>시키는 두 번째 3상 시험의 톱라인 결과를 발표한 후 주가는 13.18% 상승했다.      shares advanced 12.06% on overall strength in chip stocks. Also, B. Riley Securities analyst <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">raised the price forecast</a> on the stock from $45 to $50.</li>
<li>앰코 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>)는 전반적인 칩주 강세로 주가는 12.06% 상승했다. 또한 B. 라일리 증권(B. Riley Securities)의 분석가는 주식 가격 <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">예측</a>을 45달러에서 50달러로 높였다.</li>
<li>아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>)는 회사가 이전에 공개한 <a href="https://www.benzinga.com//node/39411935" target="_blank" rel="noreferrer noopener">제조 자동화 계획</a>의 초기 단계를 시작한 후 기업의 이정표에 도달했다고 발표한 후 주가는 11.53% 증가했다.</li>
<li>로켓 랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)는 주가는 <a href="https://www.benzinga.com//node/39429411" target="_blank" rel="noreferrer noopener">일본 기업 신스펙티브(Synspective)</a>와 도쿄에서 10개 제품 출시 계약을 체결한 후 11.32% 상승했다.</li>
<li>브레드 파이낸셜 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>)는 에버코어 ISI 그룹(Evercore ISI Group)이 이 주식을 언더퍼폼(Underperform)에서 인-라인(In-Line)으로 평가를 올리고 목표 주가를 42달러에서 45달러로 <a href="https://www.benzinga.com/quote/BFH/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정한 </a>이후 10.81% 상승했다. 또한 또한 RBC 캐피털은 해당 주식에 대해 섹터 퍼폼(Sector Perform) 등급을 유지하고 목표 주가를 38달러에서 45달러로 높였다.</li>
<li>BRF S.A.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRFS#NYSE">BRFS</a>)의 주식은 10.69% 상승했다.</li>
</ol>
위키미디어 커먼즈를 통한 사진
기사 읽기: <a href="https://kr.benzinga.com/news/%ea%b2%8c%ec%9e%84%ec%8a%a4%ed%83%91%ea%b3%bc-%ec%9e%90%eb%b9%8c%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%ea%b0%9c%ec%9d%98/" target="_blank" rel="noopener">게임스탑과 자빌은 지난주 최악의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)</a>

Comments

ImmunityBio

뉴스

에 대한 최신 뉴스 ImmunityBio (NASDAQ:IBRX) 주식

일요일, 5월 18, 2025

월요일, 1월 20, 2025

월요일, 10월 28, 2024

월요일, 6월 24, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌